Evogene (EVGN)
(Delayed Data from NSDQ)
$2.69 USD
-0.05 (-1.82%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $2.69 0.00 (0.00%) 7:16 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Evogene Ltd falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 6 | 2 | 1 | 1 | 1 |
Cost Of Goods | 2 | 1 | 1 | 1 | 0 |
Gross Profit | 4 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 28 | 31 | 25 | 22 |
Income After Depreciation & Amortization | -27 | -27 | -31 | -25 | -21 |
Non-Operating Income | 1 | 1 | 2 | 2 | 3 |
Interest Expense | 1 | 3 | 1 | 3 | 1 |
Pretax Income | -26 | -30 | -30 | -26 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -2 | -3 | -3 | -3 | -1 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -26 | -30 | -30 | -26 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -24 | -27 | -28 | -23 | -18 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -24 | -24 | -29 | -22 | -18 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 2 | 3 | 3 |
Income After Depreciation & Amortization | -27 | -27 | -31 | -25 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.57 | 4.12 | 4.04 | 2.82 | 2.58 |
Diluted EPS Before Non-Recurring Items | -5.20 | -6.50 | -6.90 | -8.30 | -7.00 |
Diluted Net EPS (GAAP) | -5.20 | -6.50 | -6.90 | -8.30 | -7.00 |
Fiscal Year end for Evogene Ltd falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.91 | 4.19 | 0.58 | 3.77 | 0.65 |
Cost Of Goods | 0.54 | 0.31 | 0.40 | 0.51 | 0.46 |
Gross Profit | 0.38 | 3.88 | 0.18 | 3.26 | 0.19 |
SG&A, R&D, and Dept/Amort Expenses | 6.48 | 7.97 | 7.81 | 7.44 | 8.10 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.10 | -4.09 | -7.63 | -4.18 | -7.91 |
Non-Operating Income | 0.24 | 0.41 | 0.36 | 0.43 | 0.39 |
Interest Expense | 0.12 | 0.17 | 0.07 | 0.11 | 0.25 |
Pretax Income | -5.98 | -3.85 | -7.34 | -3.86 | -7.76 |
Income Taxes | 0.00 | 0.00 | 0.00 | -0.01 | 0.02 |
Minority Interest | -0.57 | 0.02 | -0.74 | 0.13 | -0.76 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -5.99 | -3.85 | -7.34 | -3.86 | -7.78 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -5.42 | -3.86 | -6.60 | -3.98 | -7.02 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 5.09 | 5.06 | 5.06 | 4.89 | 4.16 |
Diluted EPS Before Non-Recurring Items | -1.06 | -0.80 | -1.30 | -0.80 | -1.70 |
Diluted Net EPS (GAAP) | -1.06 | -0.80 | -1.20 | -0.80 | -1.70 |